Despite the fact that several patients had aberrations in some genes such as CTTNB1 and CDKN2A, the specific combination of aberrations and their subtypes were unique to each individual patient, important distinctions for selecting personalized cancer therapies. The gene discussed is CDKN2A; the disease is cancer.